IQS-019|IQS 019;IQS019

Cas No.:	1630804-24-8
Chemical Name:	4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
Synonyms:	IQS 019;IQS019
SMILES:	C(NC1=CC=C(N2CCN(C)CC2)C=C1)1=NC(N)=C2C=C(C3=C(Cl)C=CC=C3Cl)C(=O)N(C)C2=N1
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively; inhibits at least 20% of the kinase activity at 0.1 uM) and an almost complete kinase inactivation at the 10 uM in a set of 17 TK/TKLs; impaires cell proliferation, reduces CXCL12-dependent cell migration, and induces caspase-dependent apoptosis; shows improved efficacy in vitro and in vivo compared to ibrutinib.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC47719	BTK inhibitor 19	BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM).
DC46928	TL-895	TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research.
DC46051	Zanubrutinib D5	Zanubrutinib D5 (BGB-3111 D5) is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor.
DC45785	Elsubrutinib	Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.
DC44005	BTK inhibitor 17	BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research.
DC42422	IBT6A hydrochloride	IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM.
DC42421	IBT6A	IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM.
DC41149	Ibrutinib deacryloylpiperidine	Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
DC41102	Acalabrutinib D4	Acalabrutinib D4 (ACP-196 D4) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor.
DC11776	G-744	G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.